In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $111.29 in the last session, up 0.14% from day before closing price of $111.13. In other words, the price has increased by $0.14 from its previous closing price. On the day, 0.62 million shares were traded. AXSM stock price reached its highest trading level at $112.01 during the session, while it also had its lowest trading level at $109.6.
Ratios:
We take a closer look at AXSM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.51 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 3.06 whereas as Long-Term Debt/Eq ratio is at 1.98.
On June 03, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $185.
On April 07, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $200.Jefferies initiated its Buy rating on April 07, 2025, with a $200 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 20 ’25 when Murdock Hunter R. sold 7,500 shares for $102.47 per share. The transaction valued at 768,525 led to the insider holds 0 shares of the business.
Murdock Hunter R. sold 6,014 shares of AXSM for $602,122 on Jun 23 ’25. The General Counsel now owns 0 shares after completing the transaction at $100.12 per share. On Jun 23 ’25, another insider, Murdock Hunter R., who serves as the Officer of the company, bought 6,014 shares for $100.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 5553538048 and an Enterprise Value of 5459843072. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.22 while its Price-to-Book (P/B) ratio in mrq is 75.87. Its current Enterprise Value per Revenue stands at 11.029 whereas that against EBITDA is -27.349.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.53, which has changed by 0.26595378 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $139.13, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 5.08%, while the 200-Day Moving Average is calculated to be 5.25%.
Shares Statistics:
According to the various share statistics, AXSM traded on average about 628.42K shares per day over the past 3-months and 472630 shares per day over the past 10 days. A total of 49.82M shares are outstanding, with a floating share count of 41.04M. Insiders hold about 17.75% of the company’s shares, while institutions hold 75.86% stake in the company. Shares short for AXSM as of 1753920000 were 3673567 with a Short Ratio of 5.85, compared to 1751241600 on 4083784. Therefore, it implies a Short% of Shares Outstanding of 3673567 and a Short% of Float of 8.7799996.
Earnings Estimates
The market rating for Axsome Therapeutics Inc (AXSM) is a result of the insights provided by 12.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.23 and low estimates of -$0.97.
Analysts are recommending an EPS of between -$2.97 and -$4.16 for the fiscal current year, implying an average EPS of -$3.63. EPS for the following year is $0.79, with 12.0 analysts recommending between $3.78 and -$2.27.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $164.1M. It ranges from a high estimate of $172.6M to a low estimate of $153.5M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $104.76MFor the next quarter, 17 analysts are estimating revenue of $186.39M. There is a high estimate of $196.84M for the next quarter, whereas the lowest estimate is $170.7M.
A total of 19 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $650.02M, while the lowest revenue estimate was $601.1M, resulting in an average revenue estimate of $623.53M. In the same quarter a year ago, actual revenue was $385.69MBased on 19 analysts’ estimates, the company’s revenue will be $973.76M in the next fiscal year. The high estimate is $1.09B and the low estimate is $838.2M.
